Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) Net Margin (2016 - 2025)

Fortress Biotech has reported Net Margin over the past 12 years, most recently at 34.26% for Q4 2025.

  • Quarterly results put Net Margin at 34.26% for Q4 2025, up 4247.0% from a year ago — trailing twelve months through Dec 2025 was 2.88% (up 9849.0% YoY), and the annual figure for FY2025 was 2.97%, up 9840.0%.
  • Net Margin for Q4 2025 was 34.26% at Fortress Biotech, down from 20.84% in the prior quarter.
  • Over the last five years, Net Margin for FBIO hit a ceiling of 81.37% in Q2 2025 and a floor of 14708.74% in Q2 2023.
  • Median Net Margin over the past 5 years was 168.89% (2022), compared with a mean of 1636.62%.
  • Biggest five-year swings in Net Margin: tumbled -1065952bps in 2023 and later surged 1461920bps in 2024.
  • Fortress Biotech's Net Margin stood at 355.83% in 2021, then tumbled by -2135bps to 7953.02% in 2022, then surged by 100bps to 28.14% in 2023, then tumbled by -173bps to 76.73% in 2024, then skyrocketed by 55bps to 34.26% in 2025.
  • The last three reported values for Net Margin were 34.26% (Q4 2025), 20.84% (Q3 2025), and 81.37% (Q2 2025) per Business Quant data.